About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
CVM - Cel-Sci Corporation| Previous Close | $7.74 | Open | $7.67 |
| Volume | 573K | Market Cap | 328.24M |
| Yield | Last Dividend |
| T Cell Surface Glycoprotein CD4 Market 2... | 07/22/21 |
| This report studies the T Cell Surface Glycoprotein CD4 Market with many aspects of the industry such as market size, market status, market trends and... | |
| Pflug Koory, LLC Buys , iShares Mornings... | 07/14/21 |
| Related Stocks: JKI , JKL , VMI , VRTX , GOOD , HUM , KMB , VHT , KEY , CBRE , HBAN , CVM , VAR , OGN , APD , GGG , MTD , SHW , | |
| June 2021 | Caldwell Canadian Value Mome... | 07/14/21 |
| June Recap: The Caldwell Canadian Value Momentum Fund (CVM) gained 2.6% in June versus a gain of 2.5% for the S&P/TSX Composite Total Return Index Mor... | |
| Cel-sci Corp (CVM) CEO Geert R Kersten B... | 07/08/21 |
| Related Stocks: CVM , | |
| CEL-SCI Corporation Issues Letter to Sha... | 07/07/21 |
| VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HeadandNeckCancer--CEL-SCI Corporation issues letter to shareholders. | |
| Discussion of Results of CEL-SCIs Phase ... | 07/02/21 |
| CEL-SCI Corporation (NYSE American: CVM) today announced that the discussion at the Annual Shareholder Meeting, on July 1, 2021 at 10:00 am EDT, regar... | |
| Why CEL-SCI Shares Are Getting Hammered ... | 06/30/21 |
| CEL-SCI Corporation (NASDAQ: CVM ) shares are trading lower by 27% at $9.33 on continued downward momentum following data from a Phase 3 Study of Mult... | |
| ASTS, CVM, VTNR and ALT among midday mov... | 06/30/21 |
| No summary available. | |
| SHAREHOLDER ALERT: Pomerantz Law Firm In... | 06/29/21 |
| NEW YORK, June 29, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CEL-SCI Corporation ("CEL-SCI" or the "Company... | |
| CEL-SCI Drops on More Details of Bought-... | 06/28/21 |
| CEL-SCI Corporation (NYSE:CVM) fell sharply early Monday. The company, earlier during the month, announced a bought deal offering of $31.7 million. Th... | |
| CEL-SCI''s Immunotherapy Achieves Surviv... | 06/28/21 |
| CEL-SCI Corporation (NYSE: CVM ) has announced results from its Phase 3 study for its immunotherapy Multikine for advanced previously untreated squamo... | |
| CEL-SCIs Multikine Immunotherapy Produce... | 06/28/21 |
| CEL-SCI Corporation (NYSE American: CVM) today announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine (Leukocyte In... | |
| Here is What Hedge Funds Think About CEL... | 06/22/21 |
| No summary available. | |
| CEL-SCI Announces the Closing of $31.7 M... | 06/11/21 |
| VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces the closing of $31.7 million bought deal offering. | |
| CEL-SCI Stock Drops After Raising $37.1M... | 06/09/21 |
| CEL-SCI Corporation (NYSE: CVM ) has increased the size of its previously announced capital raise offering to 1.4 million shares, up from 1 million sh... | |
| CEL-SCI Increases Previously Announced B... | 06/08/21 |
| CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced that, due to demand, the underwriter has agreed to increase the size of its pre... | |
| Carotid Stenotic Scan Devices Market 202... | 06/07/21 |
| Carotid Stenotic Scan Devices - Epidemiology Forecast, 2026 report provides a comprehensive analysis of the Carotid Stenotic Scan Devices epidemiology... | |
| Harvey McKenzie: Resignation of CEO and ... | 05/28/21 |
| Vancouver, British Columbia--(Newsfile Corp. - May 28, 2021) - Michael Rhodes, Chief Executive Officer of CVR Medical Corp. (the "Company") and Harvey... | |
| Resignation of CEO and Financial Advisor... | 05/28/21 |
| Treating youand your storywith courtesy and care. Our commitment to delivering the best personal service defines our business and inspires our efforts... | |
| Cvr Medical Corp (CVM.VN) drops 12.5% fo... | 05/20/21 |
| Cvr Medical Corp (TSX-V: CVM.VN) shares dropped -12.50% to end trading Thursday at $0.04 per share - a net change of $0.00. Shares traded between $0.0... | |
| Cel-Sci: Fiscal Q2 Earnings Snapshot | 05/18/21 |
| VIENNA, Va. (AP) _ Cel-Sci Corp. (CVM) on Tuesday reported a loss of $11.3 million in its fiscal second quarter. The Vienna, Virginia-based company sa... | |
| CEL-SCI Corporation Reports Second Quart... | 05/17/21 |
| CEL-SCI Corporation Reports Second Quarter Fiscal 2021 Financial Results | |
| CEL-SCI Corporation Shares Close the Wee... | 04/23/21 |
| CEL-SCI Corporation shares closed this week 39.8% higher than it did at the end of last week. The stock is currently up 109.4% year-to-date, up 98.1%... | |
| CEL-SCI Corporation Shares Close the Day... | 02/05/21 |
| CEL-SCI Corporation shares closed today 12.5% higher than it did at the end of yesterday. The stock is currently up 102.3% year-to-date, up 67.1% ove... | |
| CEL-SCI Corporation Shares Close the Wee... | 01/29/21 |
| CEL-SCI Corporation shares closed this week 75.1% higher than it did at the end of last week. The stock is currently up 114.0% year-to-date, up 80.8%... | |
| CEL-SCI Corporation Shares Near 52-Week ... | 01/29/21 |
| CEL-SCI Corporation shares closed today at 0.2% below its 52 week high of $25.00, giving the company a market cap of $991M. The stock is currently up... | |
| CEL-SCI Corporation Shares Close the Day... | 01/29/21 |
| CEL-SCI Corporation shares closed today 28.6% higher than it did at the end of yesterday. The stock is currently up 114.0% year-to-date, up 80.8% ove... | |
| CEL-SCI Corporation Shares Close the Wee... | 12/11/20 |
| CEL-SCI Corporation shares closed the week 17.8% higher than it did at the end of last week. The stock is currently up 53.4% year-to-date, up 80.7% o... | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Arbitrage Trade Analytics | Royce Wells | 72.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
